Synthaverse Valuation
Is 6NQ undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 6NQ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 6NQ's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 6NQ's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 6NQ?
Key metric: As 6NQ is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 6NQ's PE Ratio? | |
|---|---|
| PE Ratio | 68.9x |
| Earnings | zł4.45m |
| Market Cap | zł306.39m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 6.1x |
| Enterprise Value/EBITDA | 23.7x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 6NQ's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 17.8x | ||
2INV 2invest | 12.7x | n/a | €63.8m |
FYB Formycon | 12.9x | 31.5% | €827.2m |
BIO3 Biotest | 15.8x | 29.3% | €1.4b |
2FJ0 Pierrel | 29.9x | n/a | €92.8m |
6NQ Synthaverse | 68.9x | n/a | €306.4m |
Price-To-Earnings vs Peers: 6NQ is expensive based on its Price-To-Earnings Ratio (68.9x) compared to the peer average (17.8x).
Price to Earnings Ratio vs Industry
How does 6NQ's PE Ratio compare vs other companies in the European Biotechs Industry?
| 5 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 5 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 6NQ is expensive based on its Price-To-Earnings Ratio (68.9x) compared to the European Biotechs industry average (27x).
Price to Earnings Ratio vs Fair Ratio
What is 6NQ's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 68.9x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 6NQ's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Fortrea Holdings
US$1.8b
A contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide.
K67
US$18.40
7D
2.8%
1Y
-38.7%
Amneal Pharmaceuticals
US$2.6b
Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.
2DT
US$7.70
7D
1.3%
1Y
89.7%
Collegium Pharmaceutical
US$966.2m
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
354
US$29.00
7D
3.6%
1Y
22.9%